Zuvotolimod

Zuvotolimod is a myeloid cell agonist compound-linker for antibody conjugate. Zuvotolimod can be used in the research of cancer and hepatitis[1][2].

Product Specifications

CAS Number

[2355262-97-2]

UNSPSC

12352203

Target

ADC Linker

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/zuvotolimod.html

Purity

99.46

Solubility

10 mM in DMSO

Smiles

O=C(N1CC(C=C(NC(C2=CC3=C(C=C(C(N(CCC)CCC)=O)CC(N)=N3)C=C2)=O)C=N4)=C4CC1)OCC5=CC=C(NC([C@](NC([C@@](C(C)C)([H])NC(CCCCCN6C(C=CC6=O)=O)=O)=O)([H])CCCNC(N)=O)=O)C=C5

Molecular Formula

C55H70N12O10

Molecular Weight

1059.22

References & Citations

[1]Peter Armstrong Thompson, et al. Anti-liver cell or viral antigen antibody conjugate with myeloid cell agonist for treatment of hepatitis. Patent WO2019118884 A1.|[2] Sean Wesley Smith, et al. Preparation of benzazepines and their conjugates containing peptidyl linkers for the treatment of cancer and modulation of TLR8. Patent WO2020056194 A1.